Halo Therapeutics
The first of these projects is a drug that's being developed by Halo Therapeutics, a US based company that specialises in DMD and works in strong partnership with a number of muscular dystrophy charities. The drug is a derivative of a natural compound found in a species of plant. It acts as an anti-fibrotic, so it will help prevent the build-up of muscle tissue - something that worsens the effect of DMD on its sufferers. Joining Jack gave $100,000 to help fund this project.
"We are extremely pleased that Joining Jack has chosen to provide critical funds to Halo for clinical testing of HT-100 in boys with DMD," said Marc Blaustein, Halo Therapeutics CEO. "We are in a race against time to conquer DMD, and Joining Jack's financial support allows us to continue development of this promising therapeutic candidate as rapidly as possible."
Our Projects
- Solid GT
- The Newcastle Plan
- Lectureship to develop clinical trial agenda
- Reveragen
- Tamoxifen Trial
- Summit PLC
- University of Geneva Combination and Repurposing Study
- Soy Products
- Halo Therapeutics
- Alder Hey Heart Protection Study
- The Duchenne Forum
- Cannabidiol (CBD)
- A Combination Study
- DMD Programme Co-ordinator
- Elastase Inhibitors
- Understanding the causes of heart disease in DMD
- Evox Therapeutics
- Tamoxifen Open Label Extension Study
- Adult Neuromuscular Complex Care Centre
- Testosterone Extension Study
How You Can Help
There are many ways that you can help us to beat DMD.
You could simply donate online:
Find out more ways to donate to Joining Jack.
Take a look at this section to find out further ways that you can help us beat DMD.
